415 Capital is a specialist venture capital firm that partners with exceptional entrepreneurs to bring breakthrough medical technologies to patients. In addition to early- and development-stage capital, 415 leverages relationships with over 200 clinical sites and dozens of thought leaders to build value for its porfolio companies. Over the years, the 415 team has introduced over 25 breakthrough technologies to market and realized over 20 successful portfolio exits to-date, including Vesper Medical and Intact Vascular (both acquired by Philips), Claret Medical (acquired by Boston Scientific), ReCor Medical (acquired by Otsuka), CardiAQ Valve Technologies (acquired by Edwards), Atritech (acquired by Boston Scientific), CoreValve (acquired by Medtronic) and many more. The technologies we back improve patient outcomes and save lives.